|
1
|
Wadhwa R, Song S, Lee JS, Yao Y, Wei Q and
Ajani JA: Gastric cancer-molecular and clinical dimensions. Nat Rev
Clin Oncol. 10:643–655. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Szász AM, Lánczky A, Nagy Á, Förster S,
Hark K, Green JE, Boussioutas A, Busuttil R, Szabó A and Győrffy B:
Cross-validation of survival associated biomarkers in gastric
cancer using transcriptomic data of 1,065 patients. Oncotarget.
7:49322–49333. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Wu HH, Lin W and Tsai KW: Advances in
molecular biomarkers for gastric cancer: miRNAs as emerging novel
cancer markers. Expert Rev Mol Med. 16:e12014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lan H, Lu H, Wang X and Jin H: MicroRNAs
as Potential Biomarkers in Cancer: Opportunities and Challenges.
Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Costa FF: Epigenomics in cancer
management. Cancer Manag Res. 2:255–265. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Taby R and Issa JP: Cancer epigenetics. CA
Cancer J Clin. 60:376–392. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang Q, Yan C, Xin M, Han L, Zhang Y and
Sun M: Sirtuin 1 (Sirt1) overexpression in BaF3 cells contributes
to cell proliferation promotion, apoptosis resistance and
pro-inflammatory cytokine production. Med Sci Monit. 23:1477–1482.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmid G, Notaro S, Reimer D, Abdel-Azim
S, Duggan-Peer M, Holly J, Fiegl H, Rössler J, Wiedemair A, Concin
N, et al: Expression and promotor hypermethylation of miR-34a in
the various histological subtypes of ovarian cancer. BMC Cancer.
16:1022016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Welch C, Chen Y and Stallings RL:
MicroRNA-34a functions as a potential tumor suppressor by inducing
apoptosis in neuroblastoma cells. Oncogene. 26:5017–5022. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li XJ, Ren ZJ and Tang JH: MicroRNA-34a: A
potential therapeutic target in human cancer. Cell Death Dis.
5:e13272014. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Peng Y, Guo JJ, Liu YM and Wu XL:
MicroRNA-34A inhibits the growth, invasion and metastasis of
gastric cancer by targeting PDGFR and MET expression. Biosci Rep.
34:pii. e001122014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Edge SB and Compton CC: The american joint
committee on cancer: The 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pourianfar HR, Javadi A and Grollo L: A
colorimetric-based accurate method for the determination of
enterovirus 71 titer. Indian J Virol. 23:303–310. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lal A, Thomas MP, Altschuler G, Navarro F,
O'Day E, Li XL, Concepcion C, Han YC, Thiery J, Rajani DK, et al:
Capture of microRNA-bound mRNAs identifies the tumor suppressor
miR-34a as a regulator of growth factor signaling. PLoS Genet.
7:e10023632011. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Firestein R, Blander G, Michan S,
Oberdoerffer P, Ogino S, Campbell J, Bhimavarapu A, Luikenhuis S,
de Cabo R, Fuchs C, et al: The SIRT1 deacetylase suppresses
intestinal tumorigenesis and colon cancer growth. PLoS One.
3:e20202008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zeng Y, Yi R and Cullen BR: MicroRNAs and
small interfering RNAs can inhibit mRNA expression by similar
mechanisms. Proc Natl Acad Sci USA. 100:9779–9784. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ji Q, Hao X, Meng Y, Zhang M, Desano J,
Fan D and Xu L: Restoration of tumor suppressor miR-34 inhibits
human p53-mutant gastric cancer tumorspheres. BMC Cancer.
8:2662008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Leeuwen IM, Higgins M, Campbell J,
McCarthy AR, Sachweh MC, Navarro AM and Laín S: Modulation of p53
C-terminal acetylation by mdm2, p14ARF, and cytoplasmic SirT2. Mol
Cancer Ther. 12:471–480. 2013. View Article : Google Scholar
|
|
20
|
Yamakuchi M, Ferlito M and Lowenstein CJ:
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci
USA. 105:13421–13426. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xu M, Lu L, Mao B, Lü X, Wu XS, LI L and
Liu DP: Mutual inhibition between miR-34a and SIRT1 contributes to
regulation of DNA double-strand break repair. Chin Sci Bulletin.
58:979–985. 2013. View Article : Google Scholar
|
|
22
|
Ma W, Xiao GG, Mao J, Lu Y, Song B, Wang
L, Fan S, Fan P, Hou Z, Li J, et al: Dysregulation of the
miR-34a-SIRT1 axis inhibits breast cancer stemness. Oncotarget.
6:10432–10444. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Price NL, Gomes AP, Ling AJY, Duarte FV,
Martin-Montalvo A, North BJ, Agarwal B, Ye L, Ramadori G, Teodoro
JS, et al: SIRT1 is required for AMPK activation and the beneficial
effects of resveratrol on mitochondrial function. Cell Metab.
15:675–690. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Tulino R, Benjamin AC, Jolinon N, Smith
DL, Chini EN, Carnemolla A and Bates GP: SIRT1 activity is linked
to its brain region-specific phosphorylation and is impaired in
huntington's disease mice. PLoS One. 11:e01454252016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Mvunta DH, Miyamoto T, Asaka R, Yamada Y,
Ando H, Higuchi S, Ida K, Kashima H and Shiozawa T: SIRT1 regulates
the chemoresistance and invasiveness of ovarian carcinoma cells.
Transl Oncol. 10:621–631. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lynch CJ, Shah ZH, Allison SJ, Ahmed SU,
Ford J, Warnock LJ, Li H, Serrano M and Milner J: SIRT1 undergoes
alternative splicing in a novel auto-regulatory loop with p53. PLoS
One. 5:e135022010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Riquelme I, Saavedra K, Espinoza JA, Weber
H, García P, Nervi B, Garrido M, Corvalán AH, Roa JC and Bizama C:
Molecular classification of gastric cancer: Towards a
pathway-driven targeted therapy. Oncotarget. 6:24750–24779. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Peng L, Yuan Z, Li Y, Ling H, Izumi V,
Fang B, Fukasawa K, Koomen J, Chen J and Seto E: Ubiquitinated
sirtuin 1 (SIRT1) function is modulated during DNA damage-induced
cell death and survival. J Biol Chem. 290:8904–8912. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bilici A: Treatment options in patients
with metastatic gastric cancer: Current status and future
perspectives. World J Gastroenterol. 20:3905–3915. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang G, Wang Y, Xiong Y, Chen XC, Ma ML,
Cai R, Gao Y, Sun YM, Yang GS and Pang WJ: Sirt1 AS lncRNA
interacts with its mRNA to inhibit muscle formation by attenuating
function of miR-34a. Sci Rep. 6:218652016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Aoyagi K, Kouhuji K, Kizaki J, Isobe T,
Hashimoto K and Shirouzu K: Molecular targeting to treat gastric
cancer. World J Gastroenterol. 20:13741–13755. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
De Vita F, Di Martino N, Fabozzi A,
Laterza MM, Ventriglia J, Savastano B, Petrillo A, Gambardella V,
Sforza V, Marano L, et al: Clinical management of advanced gastric
cancer: The role of new molecular drugs. World J Gastroenterol.
20:14537–14558. 2014. View Article : Google Scholar
|
